Minutes from the EMA’s Committee for Medicinal Products for Human Use (CHMP) released on the 19th of May 2023: Lagevrio – molnupiravir

Re-examination of initial application procedures

Lagevrio – molnupiravir

Merck Sharp & Dohme B.V

• Treatment of coronavirus disease 2019 (COVID-19)
• The CHMP appointed a re-examination rapporteur and a re-examination Co-Rapporteur.